Showing results (201-210 of 230) with videos related to
Sort By:
Pageof 23
Cancer Discovery|September 15, 2018
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer OrganoidsSarah J Hill, Brennan Decker, Emma A Roberts, et al.British Journal of Cancer|December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumoursPanagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2016
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel TherapeuticsJoyce F Liu, Sangeetha Palakurthi, Qing Zeng, et al.International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|May 12, 2018
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)Helena M Ditzel, Kyle C Strickland, Emily E Meserve, et al.Nature Communications|March 21, 2020
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Doga C Gulhan, Julia Casado, et al.JAMA Oncology|June 14, 2019
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian CarcinomaPanagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, et al.Cancer Research|October 15, 2024
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient TumorsLouise Cadzow, Jehrod Brenneman, Erica Tobin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2017
Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian CancerDouglass W Tucker, Christopher R Getchell, Eric T McCarthy, et al.Nature Communications|May 20, 2020
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Doga C Gulhan, Julia Casado, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2012
Ovarian cancer, version 3.2012Robert J Morgan, Ronald D Alvarez, Deborah K Armstrong, et al.Pageof 23